p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition
M2 macrophages promote tumor progression and therapy resistance, whereas proimmunogenic M1 macrophages can contribute to the efficacy of cytostatic and immunotherapeutic strategies. The abundance of M2 macrophages in the immune infiltrate of many cancer types has prompted the search for strategies t...
Main Authors: | Rienk Offringa, Daniel Baumann, Jennifer Drebant, Tanja Hägele, Luisa Burger, Clara Serger, Claudia Lauenstein, Przemyslaw Dudys, Gerrit Erdmann |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002319.full |
Similar Items
-
Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
by: Daniel Baumann, et al.
Published: (2020-08-01) -
Mycobacterium tuberculosis-induced expression of granulocyte-macrophage colony stimulating factor is mediated by PI3-K/MEK1/p38 MAPK signaling pathway
by: Jang-Eun Cho, et al.
Published: (2013-04-01) -
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
by: Daniel Baumann, et al.
Published: (2020-05-01) -
Immunomodulatory Effects of Colistin on Macrophages in Rats by Activating the p38/MAPK Pathway
by: Jin Wang, et al.
Published: (2019-06-01) -
SR-A ligand and M-CSF dynamically regulate SR-A expression and function in primary macrophages via p38 MAPK activation
by: Du Liqin, et al.
Published: (2011-07-01)